[{"id":"e3b157b4-de98-48c9-916f-6f2e48d291c1","acronym":"KEYNOTE-D36","url":"https://clinicaltrials.gov/study/NCT05309421","created_at":"2022-04-04T13:52:38.861Z","updated_at":"2025-02-25T16:17:31.433Z","phase":"Phase 2","brief_title":"A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma","source_id_and_acronym":"NCT05309421 - KEYNOTE-D36","lead_sponsor":"Evaxion Biotech A/S","biomarkers":" BRAF • CD8 • CD4","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • EVX-01"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/30/2022","start_date":" 08/30/2022","primary_txt":" Primary completion: 06/28/2025","primary_completion_date":" 06/28/2025","study_txt":" Completion: 07/25/2025","study_completion_date":" 07/25/2025","last_update_posted":"2023-09-27"}]